Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fertomcidina U
- Development stage
- Phase 4
- Lead developer
- AOU Città della Salute e della Scienza di Torino
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
Fertomcidina U is a topical antiseptic solution primarily used for the treatment of oral mucosal lesions, including recurrent aphthous stomatitis, gingivitis, and periodontitis. It is a complex formulation containing iodine, sulfuric acid, and nitric acid. The drug exerts its therapeutic effect through the broad-spectrum antimicrobial properties of iodine, which oxidizes essential biological molecules in pathogens, while the acidic components may assist in the cleansing and debridement of the affected tissue. It has been evaluated in Phase 4 clinical trials comparing its efficacy to chlorhexidine for symptom relief and lesion healing in patients with minor aphthous ulcers.
- Brand names
- Fertomcidina U
02
Targets
Neuraminidase
Beyond the preview
Go deeper on Fertomcidina U.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fertomcidina U.